If you are researching weight loss injections in 2026, you have likely heard of Wegovy (Semaglutide) and the newer, more potent Mounjaro (Tirzepatide). But most information online is based on Western bodies.
Asian genetics are different.
In Thailand, we often see patients with a “Skinny Fat” profile—normal body weight but high visceral fat (hidden belly fat) and metabolic risks. This condition requires a specific medical approach.
So, which injection is better for the Asian body type? Is it the clinically proven Wegovy, or the dual-action Mounjaro? Let’s look at the data.
1. The “Thai” Proof: Why Wegovy is the Safe Bet
If you prioritize safety and local evidence, Wegovy is the gold standard. Unlike many drugs tested only in the US or Europe, Wegovy has a specific clinical trial relevant to us: the STEP 11 Trial.
- The Study: Conducted specifically in Thailand and South Korea.
- The Result: Asian participants lost an average of 13.2% to 16% of their body weight.
- Why Choose It: You have the confidence of knowing this drug was tested on our genetics, our diets, and our lifestyle. It is proven to work for Thai patients.
2. The “Metabolic Powerhouse”: Why Mounjaro Wins on Potency
Mounjaro (Tirzepatide) represents the next generation. It is the first “Dual Agonist,” targeting two hormones (GLP-1 + GIP) instead of just one.
- The Asian Data: While not tested in Thailand yet, Mounjaro has incredible results from China (SURMOUNT-CN) and Japan (SURMOUNT-J).
- The Result: In the Chinese trial, patients lost significantly more weight—up to 19.9%—compared to standard GLP-1s.
- Best For “Skinny Fat”: The added GIP hormone specifically improves how your body processes sugar and fat. This makes Mounjaro superior for reducing visceral fat—the dangerous “hidden” fat around your organs that is common in Asian genetics.
3. Side-by-Side Comparison: Asian Context
| Feature | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
| Mechanism | Single Action (GLP-1) | Dual Action (GLP-1 + GIP) |
| Asian Clinical Trial | STEP 11 (Thailand & Korea) | SURMOUNT-CN (China & Japan) |
| Weight Loss (Asian) | ~13–16% | ~15–20% |
| Best For | Patients wanting locally proven safety. | Patients with Metabolic Syndrome or insulin resistance. |
4. Price in Thailand
- Wegovy: ฿14,000 – ฿23,000 per month (depending on dose).
- Mounjaro:฿18,000 – ฿30,000+ per month.
- Doctor’s Tip: Because Asian bodies are often more sensitive to these medications, many Thai patients see excellent results on lower doses of Mounjaro (5mg or 7.5mg), which can keep the monthly cost manageable compared to the maximum dose of Wegovy.
5. The “Ozempic Face” Concern
A major concern in Thailand is facial volume loss. Losing weight too fast can make you look older.
- The Risk: Both drugs can cause this if dosed too aggressively.
- The Solution: We use a “Slow Titration” protocol. By increasing the dose slowly, we protect your facial structure while slimming your waistline. We can also combine treatment with Biostimulators to maintain collagen.
Conclusion: Which One Should You Choose?
- Choose Wegovy if: You are conservative. You want the drug that was explicitly tested in Thailand (STEP 11) and has a long safety record.
- Choose Mounjaro if: You have insulin resistance, high visceral fat, or have “stalled” on other diets. Its dual-action mechanism attacks the metabolic root cause of “Skinny Fat” more effectively than any other drug on the market.
Ready to transform your metabolic health?
Consult with Dr. Akkavich at Siam Clinic to find the right dosage for your specific genetic profile.
